PACT Pharma

About

Pact Pharma is a developer of personalized adoptive T cell therapies designed for the eradication of solid tumors.

Hayward,California,United States
101 - 250

Highlights

Details

Last Funding Type: Series C
Last Funding Money Raised: $75M
Industries: Biotechnology,Health Care,Personal Health,Pharmaceutical
Founded date: Jan 1, 2016
Number Of Employee: 101 - 250
Operating Status: Active
Legal Name: PACT Pharma, Inc.

Pact Pharma is a developer of personalized adoptive T cell therapies designed for the eradication of solid tumors.The company's therapies help in the identification of neo-epitopes that serve as private mutations for each patient's cancer as well as creates an opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens, enabling physicians to recognize and remove each patient's cancer cells.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

3

$200M

PACT Pharma has raised a total of $200M in funding over 2 rounds. Their latest funding was raised on Jan 11, 2020 from a Series C round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jan 11, 2020	Series C	$75M	11	Vida Ventures	—	Detail
May 25, 2018	Series B	$95M	6	GV	—	Detail
Dec 20, 2016	Series A	$30M	1	GV	—	Detail

Investors

Number of Lead Investors

Number of Investors

3

15

PACT Pharma is funded by 15 investors. Vida Ventures and Zhejiang Canaan Technology are the most recent investors.

Investor Name	Lead Investor	Funding Round
Vida Ventures	Yes	Series C
Zhejiang Canaan Technology	—	Series C
AbbVie Biotech Ventures	—	Series C
Casdin Capital	—	Series C
Droia Ventures	—	Series C
Foresite Capital	—	Series C
GV	—	Series C
Invus Opportunities	—	Series C
Pontifax	—	Series C
Taiho Ventures	—	Series C